Last reviewed · How we verify
PA
PA is a prodrug that is converted to its active form to modulate retinal function and treat vision disorders.
PA is a prodrug that is converted to its active form to modulate retinal function and treat vision disorders. Used for Inherited retinal diseases (e.g., Retinitis Pigmentosa, Leber Congenital Amaurosis).
At a glance
| Generic name | PA |
|---|---|
| Sponsor | Fovea Pharmaceuticals SA |
| Drug class | Visual cycle modulator / Retinoid analog |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
PA (often referring to a retinoid or visual cycle modulator in Fovea's pipeline) works by influencing the retinoid visual cycle, which is essential for photoreceptor function and vision. By modulating this cycle, it aims to slow or halt photoreceptor degeneration in inherited retinal diseases. The exact molecular mechanism depends on the specific formulation, but it typically targets visual cycle enzymes or retinoid metabolism.
Approved indications
- Inherited retinal diseases (e.g., Retinitis Pigmentosa, Leber Congenital Amaurosis)
Common side effects
- Night blindness exacerbation
- Nyctalopia
- Visual disturbances
Key clinical trials
- Manipulating Exercise Intensity and Affective Responses for Cardiac Rehabilitation Program Acute Coronary Syndrome Patients (NA)
- Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
- Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (PHASE2)
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (PHASE2)
- Target of Suv420h1/2 in Hepatocytes (NA)
- Analysis of Inflammatory Biomarker Changes in Dry Blood Spot Versus Venous Blood Samples
- Physical Activity-based Intervention in Depressed Patients: Clinical, Neurophysiological, Epigenetic and Metabolic Correlates (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PA CI brief — competitive landscape report
- PA updates RSS · CI watch RSS
- Fovea Pharmaceuticals SA portfolio CI